↑ Rising
Business
🔮 fades
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
Novartis stock experiences its worst single-day drop in over two decades following a critical Phase 3 trial failure for a rare muscle disease drug.